Developing targeted therapies for kidney diseases
Official title: Nanoparticle-targeted therapeutic development for glomerular diseases
Funded at City College of New York · NIH-11176072 · Data updated 2026-11-12
This study is working on new ways to help treat kidney diseases by using tiny particles to deliver medicine directly to the kidneys, especially for patients with chronic or severe kidney issues, and it aims to help those who are most affected, like many in the African American community.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | City College of New York NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | August 23, 2024 |
| Project end | March 31, 2029 |
| Funding year | 2025 |
| Award (this year) | $262,975 |
| NIH project number | 5U54MD017979-02 |
| Project ID | NIH-11176072 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals diagnosed with chronic kidney disease or end-stage kidney disease, particularly those from African American communities.
✕Less likely to help
Patients with kidney diseases not related to glomerular damage or those who are not eligible for new therapeutic interventions may not benefit from this research.
What this research studies
This research focuses on creating innovative therapies specifically designed to treat glomerular diseases, which are conditions affecting the kidney's filtering units. The project involves a collaborative team of experts in biomedical engineering, cell biology, nephrology, and pharmacology. By utilizing biocompatible nanoparticles, the research aims to enhance the delivery of therapeutic agents directly to the kidneys, potentially improving treatment outcomes for patients with chronic kidney disease and end-stage kidney disease. The approach is designed to address significant health disparities, particularly among African American populations who are disproportionately affected by these conditions.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for kidney diseases, reducing the need for dialysis and transplants.
How similar studies have gone: Previous research has shown promise in using targeted nanoparticle therapies for various conditions, suggesting potential success for this novel approach in kidney disease treatment.
Where this research is happening
-
City College of New York
New York, United States Active
Researchers
- Principal investigator: Williams, Ryan Martin — City College of New York
- Study coordinator: Williams, Ryan Martin
Related research
Other NIH-funded projects on the same topics.
-
Nonpeptide drugs to boost nerve growth for spinal cord repair
A study in animals explores small molecule drugs that can cross into the brain and help nerve fibers regrow after spinal cord injury, with the goal of restoring some function.
-
Onsite PTSD Treatment to Improve MOUD Outcomes for people who inject drugs
A community-based program will adapt a PTSD therapy and deliver it alongside opioid-use treatments to help people who inject drugs stay engaged in care and improve outcomes.
-
Understanding how neuron numbers and wiring patterns are set in the brain
A scientist at a major university is studying how sensory neurons determine how many there should be and how large their branches are, using fruit fly brain cells to learn about brain development and potentially human brain injuries.
-
Community Outreach and Education Core to Advance Cancer Prevention and Equity
A community-based program in New York partners CCNY and MSK to spread proven cancer prevention and early detection practices and to pave the way for precision prevention in diverse communities.
-
Cancer research education and mentorship program for students and early-career investigators
A program to mentor and give hands-on cancer research experience to undergraduate and graduate students and early-stage investigators.
-
Planning and Evaluation Core for Translational Cancer Research Partnership
A planning and evaluation program helps cancer care partners coordinate, monitor progress, and share findings to move new cancer research into real patient benefits.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.